| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy (NCT06414304) | OncoAtlas LLC | 2022-06-01 |
| Role of Immunoscore® in Stage II-III Colorectal Cancer (NCT05422547) | D'Or Institute for Research and Education | 2022-04-01 |
| Performance of Artificial Intelligence in Colonoscopy for Right Colon Polyp Detection (NCT06216405) | Groupe Hospitalier Diaconesses Croix Saint-Simon | 2022-01-20 |
| LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis (NCT05186116) | Azienda Ospedaliero-Universitaria di Modena | 2022-01-01 |
| Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas (NCT04920032) | University of California, Irvine | 2021-08-26 |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (NCT04963283) | University of Colorado, Denver | 2021-06-23 |
| The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery (NCT05872334) | Samsung Medical Center | 2021-06-01 |
| Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial (NCT04475159) | Prof. Aviram Nissan | 2020-08-01 |
| Validation of Aer-O-Scope Colonoscope System Cecal Intubation (NCT03949777) | GI View Ltd. | 2020-01-06 |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery (NCT04068103) | NRG Oncology | 2019-12-16 |
| Peptide-based Immunization for Colon- and and Pancreas-carcinoma (NCT03871790) | CENTOGENE GmbH Rostock | 2019-04-01 |
| Audit of Surgery for Colorectal Cancer (NCT04349384) | Institut National d'Oncologie, Morocco | 2018-01-01 |
| Treatment and Outcomes of Stage III Colon Cancer in Patients 80 Years of Age and Older (NCT04526314) | Registre des Tumeurs Digestives du Finistère | 2018-01-01 |
| S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (NCT03365882) | SWOG Cancer Research Network | 2017-11-27 |
| Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559) | National Cancer Institute (NCI) | 2017-10-16 |
| The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon (NCT04003181) | University of Aarhus | 2017-09-28 |
| Study of the Immune Response in Colon Adenocarcinoma (NCT03015038) | Institut National de la Santé Et de la Recherche Médicale, France | 2017-02-05 |
| Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy (NCT02569723) | Edward Kim | 2015-10-16 |
| Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer (NCT02393755) | Roswell Park Cancer Institute | 2015-05-08 |
| Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer (NCT02368886) | Academic and Community Cancer Research United | 2015-03-27 |
| Whole-Exome Sequencing (WES) of Cancer Patients (NCT02127359) | Dana-Farber Cancer Institute | 2012-09-01 |
| Molecular Profiling of Colorectal Cancer (NCT04863768) | Hellenic Cooperative Oncology Group | 2006-01-01 |
| Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (NCT00217737) | National Cancer Institute (NCI) | 2005-09-06 |
| Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer (NCT00096278) | National Cancer Institute (NCI) | 2004-09-15 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer (NCT02575508) | Roswell Park Cancer Institute | |